Skip to content
Head to head

Erasca vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ERAS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ERAS +374.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
ERASVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.61515.02
Change today-4.29%-1.08%
1-year return+389.6%+22.0%
Market cap$4.78B$130.58B
52-week range2.81 – 24.28412.27 – 568.67
Valuation
P/E (TTM)-14.0333.14
P/E percentile, own 5-yr range12th99th
P/B5.216.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.4415.32
Net profit (TTM)$-154.42M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-259.24M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership89.4%96.8%
Insider activity (12mo)38 buy / 12 sell28 buy / 22 sell
Short interest (% of float)10.6%1.9%
Analyst consensus67% buy / 33% hold (6)95% buy / 5% hold (21)
Analyst price target$25 (+81%)$624 (+21%)
StockVane view
StockVane Quant RatingD (100)C (68)
Company
Employees1036,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.